HAYWARD, Calif.--(BUSINESS WIRE)--Moximed®, Inc. developer of the KineSpring® System, a joint unloading knee implant for pre-arthroplasty patients, today announced that it has been named by FierceMedicalDevices as one of 2015’s Fierce 15, designating it as one of the most promising private med tech companies in the industry.
“We are pleased to be recognized as one the Fierce 15 for 2015 and honored to join the list of distinguished award recipients,” said CEO Kevin Sidow. “We are excited and encouraged by the growing recognition from surgeons and patients worldwide that our unloading therapy may help maintain an active, productive, and high quality lifestyle for those suffering from osteoarthritis.”
Moximed provides innovative joint unloading options for pre-arthroplasty patients with mild to moderate knee osteoarthritis. These patients find conservative therapy, such as pain medication and knee braces, unsuccessful and demand a less invasive alternative to joint replacement. The joint sparing KineSpring System cushions the knee from excessive loading and maintains future treatment options. The KineSpring System, which is CE marked and available in major European markets, has been implanted in over 1,000 cases worldwide. It is investigational in the US.
Osteoarthritis (OA), the most common form of arthritis, is a degenerative disease affecting the hands, knees, hips, feet and spine. According to the Centers for Disease Control and Prevention (CDC), OA affects 27 million adults in the US. It is caused by changes in cartilage, the soft tissue that cushions and protects bone, leading to pain and changes in the shape of the joint. In knee OA, as the cartilage wears away, the bone ends may begin to rub against each other, causing severe pain. While drugs and certain cartilage repair procedures may temporarily relieve pain, they often do not treat the underlying problems that led to OA. Conversely, research suggests that if the excess stress on the joint is removed, as with the KineSpring System, pain may decrease and the natural joint tissues may demonstrate some recovery.
Moximed, Inc. is dedicated to improving the standard of care for patients with osteoarthritis (OA). OA, the most common form of arthritis, leads to a breakdown of the joint’s cartilage and often results in joint pain and loss of motion. Moximed is supported by world-leading venture investors including New Enterprise Associates (NEA), Vertex Venture Holdings Ltd., Gilde Healthcare Partners, Morgenthaler Ventures, and GBS Venture Partners. More information can be found at www.moximed.com.
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceMedicalDevices’ fourth annual Fierce 15 selection. A complete list of “Fierce 15” companies can be found online at www.fiercemedicaldevices.com/fierce15.
An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, FierceMedicalDevices provides subscribers with an authoritative analysis of the day's top stories. Every year FierceMedicalDevices evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
FierceMedicalDevices keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical devices and diagnostics. More than 90,000 top industry professionals rely on FierceMedicalDevices for an insider briefing on the day's top stories. Signup is free at www.fiercemedicaldevices.com/sign-up.